Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to -$0.21.

  • Altimmune's EPS (Basic) rose 3437.5% to -$0.21 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.07, marking a year-over-year increase of 3184.71%. This contributed to the annual value of -$1.34 for FY2024, which is 1936.1% up from last year.
  • As of Q3 2025, Altimmune's EPS (Basic) stood at -$0.21, which was up 3437.5% from -$0.27 recorded in Q2 2025.
  • Altimmune's 5-year EPS (Basic) high stood at -$0.21 for Q3 2025, and its period low was -$0.81 during Q3 2021.
  • Its 5-year average for EPS (Basic) is -$0.42, with a median of -$0.39 in 2023.
  • In the last 5 years, Altimmune's EPS (Basic) plummeted by 5000.0% in 2021 and then surged by 4478.16% in 2024.
  • Over the past 5 years, Altimmune's EPS (Basic) (Quarter) stood at -$0.58 in 2021, then grew by 20.23% to -$0.46 in 2022, then fell by 28.74% to -$0.59 in 2023, then surged by 44.78% to -$0.33 in 2024, then skyrocketed by 36.0% to -$0.21 in 2025.
  • Its EPS (Basic) was -$0.21 in Q3 2025, compared to -$0.27 in Q2 2025 and -$0.26 in Q1 2025.